These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 28183276)

  • 1. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
    BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
    Newsome SD; Scott TF; Arnold DL; Altincatal A; Naylor ML
    Mult Scler Relat Disord; 2022 Jan; 57():103367. PubMed ID: 35158473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
    Arnold DL; You X; Castrillo-Viguera C
    J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
    Newsome SD; Kieseier BC; Arnold DL; Shang S; Liu S; Hung S; Sabatella G
    J Neurol; 2016 Sep; 263(9):1778-87. PubMed ID: 27314959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
    Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
    Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
    Kieseier BC; Arnold DL; Balcer LJ; Boyko AA; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A; Sheikh SI; Calabresi PA
    Mult Scler; 2015 Jul; 21(8):1025-35. PubMed ID: 25432952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
    Zivadinov R; Dwyer MG; Markovic-Plese S; Kennedy C; Bergsland N; Ramasamy DP; Durfee J; Hojnacki D; Hayward B; Dangond F; Weinstock-Guttman B
    PLoS One; 2014; 9(3):e91098. PubMed ID: 24625687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
    Coyle PK; Shang S; Xiao Z; Dong Q; Castrillo-Viguera C
    Mult Scler Relat Disord; 2018 May; 22():134-138. PubMed ID: 29679749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.
    Hang Y; Hu X; Zhang J; Liu S; Deykin A; Nestorov I
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):371-83. PubMed ID: 27299457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.
    Arnold DL; Shang S; Dong Q; Meergans M; Naylor ML
    Ther Adv Neurol Disord; 2018; 11():1756286418795085. PubMed ID: 30181780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Hoy SM
    CNS Drugs; 2015 Feb; 29(2):171-9. PubMed ID: 25666445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
    Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of peginterferon-β-1a in the therapy of multiplex sclerosis].
    Simó M; Iljicsov A
    Ideggyogy Sz; 2017 Nov; 70(11-12):365-368. PubMed ID: 29870644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.